scholarly journals Adherence to Triple-Free-Drug Combination Therapies Among Patients With Cardiovascular Disease

2020 ◽  
Vol 125 (9) ◽  
pp. 1429-1435
Author(s):  
Niccolò Lombardi ◽  
Giada Crescioli ◽  
Monica Simonetti ◽  
Ettore Marconi ◽  
Alfredo Vannacci ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Drug Combination ◽  
Free Drug ◽  
Combination Therapies

scholarly journals Co-delivery of paclitaxel and cisplatin with biocompatible PLGA–PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models

2017 ◽  
Vol 5 (30) ◽  
pp. 6049-6057 ◽  
Author(s):  
Jing Tian ◽  
Yuanzeng Min ◽  
Zachary Rodgers ◽  
Kin Man Au ◽  
C. Tilden Hagan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Drug Combination ◽  
Free Drug ◽  
Small Cell ◽  
Small Cell Lung ◽  
Therapeutic Ratio ◽  
Cancer Models

Nanoparticles co-loaded with paclitaxel and cisplatin potently enhance chemoradiotherapy in non-small cell lung cancer models versus the conventional free drug combination by delivering a precise therapeutic ratio.

scholarly journals Systematic measurement of combination drug landscapes to predict in vivo treatment outcomes for tuberculosis

2021 ◽  
Author(s):  
Jonah Larkins-Ford ◽  
Talia Greenstein ◽  
Nhi Van ◽  
Yonatan N. Degefu ◽  
Michaela C. Olson ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Treatment Outcomes ◽  
Mouse Models ◽  
Drug Combination ◽  
Combination Therapies ◽  
Therapy Outcomes ◽  
Combination Drug ◽  
Shorten Treatment Duration

AbstractA lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis. Variation in Mycobacterium tuberculosis drug response is created by the differing microenvironments in lesions, which generate different bacterial drug susceptibilities. To better realize the potential of combination therapy to shorten treatment duration, multidrug therapy design should deliberately explore the vast combination space. We face a significant scaling challenge in making systematic drug combination measurements because it is not practical to use animal models for comprehensive drug combination studies, nor are there well-validated high-throughput in vitro models that predict animal outcomes. We hypothesized that we could both prioritize combination therapies and quantify the predictive power of various in vitro models for drug development using a dataset of drug combination dose responses measured in multiple in vitro models. We systematically measured M. tuberculosis response to all 2- and 3-drug combinations among ten antibiotics in eight conditions that reproduce lesion microenvironments. Applying machine learning to this comprehensive dataset, we developed classifiers predictive of multidrug treatment outcome in a mouse model of disease relapse. We trained classifiers on multiple mouse models and identified ensembles of in vitro models that best describe in vivo treatment outcomes. Furthermore, we found that combination synergies are less important for predicting outcome than metrics of potency. Here, we map a path forward to rationally prioritize combinations for animal and clinical studies using systematic drug combination measurements with validated in vitro models. Our pipeline is generalizable to other difficult-to-treat diseases requiring combination therapies.One Sentence SummarySignatures of in vitro potency and drug interaction measurements predict combination therapy outcomes in mouse models of tuberculosis.

COMPARISON OF EFFICACY OF TELMISARTAN AND AMLODIPINE IN PATIENTS OF HYPERTENSION PRESCRIBED AS FREE DRUG AND AS FIXED DOSE COMBINATION.

2021 ◽  
pp. 53-55
Author(s):  
Ritu shitak ◽  
Anurag thakur ◽  
Malvika shitak ◽  
Sanjay sharma
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Vascular Disease ◽  
Diastolic Blood Pressure ◽  
Drug Combination ◽  
Free Drug ◽  
Drug Combinations ◽  
Fixed Dose ◽  
Newly Diagnosed ◽  
Dose Combination

INTRODUCTION: HTN remains one of the major preventable risk factors for coronary events, cerebral-vascular disease, heart failure, peripheral vascular disease and progression of kidney disease. Most patients with HTN will require more than one drug to achieve BP target. In addition, around 24% to 32% of patients will require a combination of more than two drugs to achieve BP targets. Combination therapy for HTN may be delivered either as free or xed drug combinations. In a free drug combination, each BP-lowering drug is administered in a separate pill, while in a xed drug combination two or more agents are combined in a single pill (SPC). SPCs may offer several advantages over free drug combinations, such as better compliance and simplicity of treatment. MATERIAL AND METHOD: Study was conducted for a span of one year. Every patient coming to medicine OPD for the treatment of hypertension, who has already been prescribed 40mg Telmisartan or 5mg amlodipine individually were included also the newly diagnosed patients for essential hypertension were included. INCLUSION CRITERIA: (a) 18- 60 years, Adults of either sex (b) Newly diagnosed patients of essential hypertension (c) Already diagnosed old patients on treatment for essential hypertension with 40mg Telmisartan or 5mg Amlodipine. EXCLUSION CRITERIA:(a) Patients with chronic diseases e.g. Diabetes mellitus, CKD & CAD(b) Pregnant & lactating females. RESULTS:Total 267 patients were enrolled in the study. Age and sex wise distribution was given in table no. 1.1. 138 patients were started on telmisartan and amlodipine free drug and 129 patients were started on telmisartan and amlodipine xed drug. Majority of patients were less than 60 years and 121(45.3%) patients were male and 146(54.7%) patients were female. 138 Patients were started on telmisartan and amlodipine free drug group. 28.3% patients were on amlodipine and 25.4% patients were on telmisartan where as 46.4% patients were not taking any antihypertensive treatment and mean systolic and diastolic blood pressure in this group was 168.3±14.2: 95.4±7.2. 129 patients were started on telmisartan and amlodipine xed dose combination. 31% patients were on amlodipine and 24.8% patients were on telmisartan where as 44.2% were not taking any drugs and mean systolic and diastolic blood pressure in this group was 167.8±15.6: 95.7±7.1. CONCLUSION: Telmisartan/amlodipine combination when administered separately at different times of the day showed good to excellent responsea

scholarly journals In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 752 ◽  
Author(s):  
Loujin Houdaihed ◽  
James Christopher Evans ◽  
Christine Allen
Keyword(s):  
Drug Combination ◽  
Drug Exposure ◽  
Area Under The Curve ◽  
Growth Factor Receptor ◽  
Body Weight Loss ◽  
Free Drug ◽  
Equivalent Dose ◽  
Pharmacokinetic Parameters ◽  
In Vivo Evaluation

A synergistic combination of paclitaxel (PTX) and everolimus (EVER) can allow for lower drug doses, reducing the toxicities associated with PTX, while maintaining therapeutic efficacy. Polymeric nanoparticles (NPs) of high stability provide opportunities to modify the toxicity profile of the drugs by ensuring their delivery to the tumor site at the synergistic ratio while limiting systemic drug exposure and the toxicities that result. The goal of the current study is to evaluate the in vivo fate of human epidermal factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) dual-targeted PTX+EVER-loaded NPs (Dual-NPs) in an MDA-MB-231-H2N breast cancer (BC) tumor-bearing mouse model. The pharmacokinetic parameters, plasma area under the curve (AUC) and half-life (t1/2z) were found to be 20-fold and 3 to 4-fold higher, respectively, for the drugs when administered in the Dual-NPs in comparison to the free-drug combination (i.e., PTX+EVER) at an equivalent dose of PTX. While maintaining anti-tumor efficacy, the levels of body weight loss were significantly lower (p < 0.0001) and the overall degree of neurotoxicity was reduced with Dual-NPs treatment in comparison to the free-drug combination when administered at an equivalent dose of PTX. This study suggests that Dual-NPs present a promising platform for the delivery of the PTX and EVER combination with the potential to reduce severe PTX-induced toxicities and in turn, improve quality of life for patients with BC.

Sign in / Sign up

Export Citation Format

Share Document